Thinly traded nano cap Chembio Diagnostics (NASDAQ:CEMI) jumps 31% premarket on the heels of a $4M order from a buyer in Brazil for its DPP COVID-19 IgM/IgG point-of-care blood test.
The customer, Bio-Manguinhos, is a subsidiary of a
foundation responsible for the development of vaccines, drugs and
diagnostics for (principally) the national public health system.
The company’s in-country subsidiary has filed for emergency use authorization of the test there.
https://seekingalpha.com/news/3553728-chembio-up-31-premarket-on-big-order-for-covidminus-19-test
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.